Latest press releases
Clinical trial data unveil a driver of FGFR inhibitor response in gastric cancer - collaborative study published in the journal Cancer Discovery
Scientists from AstraZeneca’s Oncology Innovative Medicines Unit, the Institute of Cancer Research, London and the Royal Marsden Foundation Trust, recently published the results of a clinical biomarker study in solid tumours. The publication defines a potential driver for clinical responses to fibroblast growth factor receptor inhibitors in gastric cancers.
Low- and middle-income countries at risk from rising stroke burden, new Economist Intelligence Unit report finds
As part of our ongoing commitment to exploring unmet need across the spectrum of atherothrombotic disease, including stroke, AstraZeneca is pleased to support a new report from The Economist Intelligence Unit (EIU).
AstraZeneca supports World Ovarian Cancer Day 2016 - Play the Know and Tell game
At AstraZeneca, we are committed to raising awareness of ovarian cancer to ensure that every woman is fully informed about the symptoms and the impact of the disease. It is our goal to leave “no woman untold” about the disease.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 970733.011
Date of next review: April 2017